In the interview, Professor Helen systematically elaborated on the current situation, challenges, and development directions of global asthma diagnosis and treatment. She pointed out that there are two core issues in current global asthma management: insufficient diagnosis rate and low accessibility to effective drugs. Although asthma has typical symptoms, in many regions, due to the lack of awareness among the public and primary healthcare workers and lack of diagnostic tools, a large number of patients fail to receive timely diagnosis. Meanwhile, asthma patients in many countries cannot access affordable and effective drugs, resulting in a high mortality rate related to asthma. Most of these death cases could be avoided through standardized treatment.

Helen教授在采访中系统阐述了全球哮喘诊疗的现状、挑战与发展方向。她指出，当前全球哮喘管理存在两大核心问题：诊断率不足与有效药物可及性低。尽管哮喘具有典型症状表现，但在许多地区，由于公众和基层医疗人员对其认知不足，加之诊断手段匮乏，大量患者未能获得及时诊断。同时，许多国家的哮喘患者无法获得负担得起的有效药物，导致哮喘相关的死亡率居高不下，而这些死亡案例大多可通过规范治疗避免。

Regarding the issue of how to detect asthma patients early and ensure they take medications in a timely manner, Professor Helen emphasized the importance of education. She proposed that it is necessary to improve the awareness of patients, community medical workers, etc, so they can recognize the symptoms of asthma. By using multimedia forms such as videos to visually present the characteristic symptoms and signs of asthma, this dynamic way of presentation is more effective in dissemination than traditional written descriptions. In terms of the allocation of diagnostic resources, she affirmed that some regions in China have been equipped with advanced equipment such as pulmonary function tests. However, she suggested strengthening the construction of primary healthcare units. Even providing simple peak flow meters can significantly enhance the ability of early diagnosis.

针对如何早期发现哮喘患者并确保他们及时用药的问题，Helen教授强调了教育的重要性。她提出，需提升患者、社区医务工作者等群体的疾病认知水平，使其能够识别哮喘症状。通过视频等多媒体形式直观呈现哮喘症状特征，这种动态展示方式较传统文字描述更具传播效力。在诊断资源配置方面，她肯定中国部分地区已配备肺功能检测等先进设备，但建议加强基层医疗单位建设，即使提供简易峰流速仪，也能显著提升早期诊断能力。

When talking about the update of the GINA 2025, Professor Helen put forward three key points: First, the combination therapy of ICS + formoterol, called anti-inflammatory reliever treatment, is recommended as the preferred treatment for most asthma patients of various severities. This combination simplifies the treatment process and reduces the risk of severe attacks. Second, diagnostic criteria for asthma in children aged 5 years and under are included for the first time, providing a basis for early intervention. Third, the principle of individualized treatment, not just with medications, is strengthened for patients who have persistent symptoms or exacerbations despite standard therapy.

谈及全球哮喘防治创议（GINA2025）指南更新，Helen教授提出了三个重点内容：一是推荐将吸入性糖皮质激素（ICS）与福莫特罗联合治疗（即抗炎缓解治疗）作为大多数不同程度哮喘患者的首选治疗方案，该组合在简化治疗流程的同时，可降低严重发作风险；二是首次纳入5岁以下儿童哮喘诊断标准，为早期干预提供科学依据；三是针对经标准治疗后仍存在持续症状或病情加重的患者，强调需强化个体化治疗原则，而非仅依赖药物治疗。

Finally, Professor Helen highly praised the "Guidelines for the Prevention and Treatment of Bronchial Asthma (2024 Edition)" issued in China (hereinafter referred to as the Chinese guidelines). She believed that the Chinese guidelines are consistent with the core recommendations of the GINA 2025 guidelines. At the same time, they fully consider the country's medical practice and resource situation, reflecting the organic combination of international evidence and local reality.

最后，Helen 教授对中国发布的《支气管哮喘防治指南（2024年版）》（以下简称中国指南）给予了高度评价。她认为，中国指南与GINA2025指南在核心推荐上保持一致，同时充分考虑了本国的医疗实践和资源状况，体现了国际经验与本土实际的有机结合。

 中国医学论坛报今日呼吸采写